SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients
Main finding · UCResult — go to the resultAdjusted hazard ratio 0.99 95 % CI 0.77–1.27Authors' conclusion
SGLT2 inhibitor use was not associated with an increased risk of UC, with potential protective associations in specific subgroups requiring further investigation.
Study context
- Population
- Patients with T2D, Taiwan's National Health Insurance Database, 2016–2021
- Exposure
- SGLT2i vs DPP-4i users
- Outcome
- Incidence of urothelial carcinoma (UC), including bladder cancer and upper tract UC (UTUC)
- Follow-up
- Mean 2.62 years
Methodological detailsinverse probability of treatment weighting, outcomes assessed from one year after treatment initiation
- Inverse probability of treatment weighting
- Outcomes assessed from one year after treatment initiation
Main finding
UC
Adjusted hazard ratio
0.99
95 % CI 0.77–1.27
SGLT2vs DPP4
aHR 0.99 (95 % CI 0.77–1.27)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Bladder cancer and upper tract urothelial carcinoma (UTUC)
- Null association consistent for both bladder cancer and UTUC
Urothelial carcinoma (UC) by individual drug type or cumulative drug days
- No significant associations by individual drug type or cumulative drug days
Exploratory sensitivity analyses
- Some trends, but none robustly significant after accounting for multiple comparisons
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
SGLT2 inhibitor and urothelial carcinoma incidence in type 2 diabetes patients. Diabetes Metab. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →